107 results about "C-peptide" patented technology

Novel pro-insulin having specific amino acid and/or nucleic acid modifications suitable for improved methods of insulin production are provided. Novel and highly efficient processes for preparing the pro-insulin preparations and preparations containing them are also disclosed. The novel pro-insulin preparations may be converted into human insulin useful in therapeutic preparations. Novel peptides of the C-peptide, and N terminus, including RREAEALQVGQVELGGGPGAGSLQPLALEGSLQAR (SEQ ID NO: 32), and MHHHHHHGGR (SEQ ID NO: 2) respectively are provided, as well as the unique nucleic acid molecules encoding them.

The present invention relates to a specific C-peptide assay method which can eliminate all interference due to proinsulin and its intermediates, in particular des-31,32-proinsulin and/or des-64,65-proinsulin. It also relates to antibodies for carrying out this assay.

The invention discloses a C-peptide micropore plate type magnetic granule chemoluminescence immunoassay measuring kit and a preparation method thereof. The kit comprises: (1) a C-peptide calibration sample, (2) magnetic granules coated by a C-peptide monoclonal antibody, (3) another monoclonal antibody or a polyclonal antibody marked by horse radish peroxidase (HRP), (4) a micropore plate, (5) washing solution and (6) chemoluminescence substrate solution on which the enzyme acts. The preparation method for preparing the kit further comprises the steps of preparing the calibration sample, preparing the magnetic granules coated by the C-peptide antibody, marking the C-peptide antibody with the horse radish peroxidase (HRP), preparing the washing solution and preparing the chemoluminescence substrate solution. The kit is simple, convenient, fast, sensitive, stable and the like.

Provided herein are methods of modulating hormone concentrations in a subject comprising the administration of a composition comprising a chemosensory receptor ligand, wherein the composition is adapted to deliver the ligand to one or more regions of the intestine of said subject. Also provided are methods directed to the modulation of circulating concentrations of one or more of GLP-1 (total), GLP-1 (active), GLP-2, oxyntomodulin, PYY (total), PYY 3-36, CCK, GIP, insulin, C-peptide, glycentin, uroguanylin amylin, and ghrelin (total), ghrelin (active) and glucagon.

The invention relates to a latex enhanced immunoturbidimetry kit for measuring the content of C peptide in human serum, a preparation method of the kit and a method for detecting the content of C peptide in human serum by use of the kit. The kit comprises a first reagent, a second reagent and a calibrator, wherein the first reagent contains buffer solution, electrolyte, a surface active agent, a stabilizing agent, a reaction enhancer and a preservative; the second reagent contains buffer solution, electrolyte, a surface active agent, a preservative and anti-human C peptide antibody enveloped sensitization polystyrene latex particles; and the calibrator contains buffer solution, a surface active agent, a stabilizing agent, a preservative and human C peptide protein. Compared with the existing kit used clinically, the kit provided by the invention has strong specificity, high sensitivity and high accuracy, the kit is suitable for biochemical analyzers of common detection mechanism, has short detection time, can be operated conveniently, has low detection cost, has no radioactive contamination, and is suitable for popularization and application clinically.

Production of beta-cells from stem cells from pluripotent stem cells have always been significantly lacking in at least one of the following properties: 1) functional properties related to insulin-production and glucose signaling response, 2) mature phenotype such as biochemical markers or cell structures, 3) efficiency in production of differentiated cells. Described herein is multistep differentiation protocol which substantially overcomes all of the existing limitations. Pluripotent stem cells, including induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) can be differentiated using an embryoid body (EB) formation step, followed by B maturation via endothelial cells (EC) co-culturing and incubation with a sequential series of bone morphogenic protein (BMP)-related growth factor cocktails. The resulting cells displayed functional properties, including insulin-production and glucose signaling response, and mature phenotype of C-peptide expression.

The invention discloses a C-peptide chemiluminescence immunodetection kit, a preparation method and a detection method therefor, belongs to the field of the immunoassay, and solves the problems of lowsensitivity, long reaction time, and high cost of an existing C-P detection method. The kit comprises magnetic particles coated by the streptavidin; the C peptide antibody labeled by the biotin; theC peptide antibody labeled by the acridinium ester; the wash buffer; the chemoluminescence pre-trigger solution; a calibrator; and a quality control product. The detection method is as follows: the C-peptide antigen in the sample is immunologically reacted with the C-peptide antibody labeled by the biotin and the C peptide antibody labeled by the acridinium ester to form a biotin-C peptide antibody-C peptide antigen-C peptide antibody-acridinium ester solvent; the magnetic particles coated by the streptavidin are combined with the biotin to form a magnetic bead-streptavidin-biotin-C peptide antibody-C peptide antigen-C-peptide antibody-acridinium ester complex; and the concentration of the C peptide is calculated by adding the washing buffer and the like. According to the C-peptide chemiluminescence immunodetection kit, the preparation method and the detection method therefor, the sensitivity is high, the specificity is good, the reaction time is short, and the cost is low.

Methods are described for determining the amount of insulin in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques. Also provided herein are mass spectrometric methods for detecting and quantifying insulin and b-chain in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.

Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.

Glargine proinsulin sconstructs that have a modified C-peptide amino acid and/or nucleic acid sequence for producing glargine insulin analogs are provided. Highly efficient processes for preparing the glargine insulin analogs and improved preparations containing the glargine insulin analogs prepared according to the methods described herein are also provided.

The invention discloses a composite probiotic liquid for preventing diabetes and controlling body weight and a preparation method thereof. The composite probiotic liquid contains saccharomyces boulardii, acetobacter xylinum, lactobacillus plantarum, bifidobacterium adolescentis, bacillus licheniformis, clostridium butyricum, arabinose, xylooligosaccharide and bacterial cellulose and the like. After probiotics and prebiotics of the composite probiotic liquid enter the human body, the absorption of glycogens such as glucose by the intestinal tract can be quickly reduced, and thus the body weight is controlled and blood glucose is reduced. Clinical test results indicate that for a patient who orally administers the composite probiotic liquid, it is determined preliminarily that the composite probiotic liquid is more excellent than pure application of metformin in the aspects of time for blood glucose to meet the standard, sugar tolerance improvement, insulin improvement and c-peptide release, and has a remarkable weight loss effect. In addition, the composite probiotic liquid indeed has curative effects in the aspects of functions of improving insulin resistance and protecting islet cells and has no side effect.

The invention features compositions comprising insulin and C-peptide and methods for treating diabetes, using such compositions. The invention further features compositions comprising insulin analogues and C-peptide and the uses thereof for treating diabetes.

There is provided an improved efficient method for differentiating stem cells into pancreatic endoderm cells and pancreatic hormone expressing and secreting cells which express Pdx-1 and C-peptide. The invention further provides screening methods for detecting factors of interest that will affect the differentiation of the stem cells into pancreatic endoderm cells.

The invention relates to a human relaxin 2 precursor and a preparation method thereof. According to the human relaxin 2 precursor, a B chain and an A chain of a natural human relaxin 2 are connected through an AsnGlyPheAsnGly artificial C peptide in a B-C-A order, so as to form a structure of a non-natural human relaxin 2 precursor. An amino acid sequence of the human relaxin 2 precursor is shown by a sequence 1 in a sequence list and is named as rhR2. According to the human relaxin 2 precursor and an optimized gene thereof, provided by the invention, a secreted expression amount of the human relaxin 2 precursor in pichia pastoris is greatly improved. The C peptide of the human relaxin 2 precursor is removed by using cheap hydroxyl amine rather than expensive TPCK (Tosyl-Phenylalanine Chloromethyl-Ketone)-trypsinase, so that the cost of removing the C peptide is reduced.

This invention relates to one human serum insulin content and C-peptide chemical test method in clinical serum immune test technique, which uses human serum insulin quantitative test agent case to test human serum insulin content and human serum C-peptide agent case to test human serum C-peptide content.

Methods are described for diagnosing or prognosing insulin resistance in diabetic and pre-diabetic patients, the method comprising determining the amount of insulin and C-peptide in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.

The invention belongs to the field of medical detection and discloses a chemiluminescence assay kit for detecting C-peptide content in serum and a detection method. The assay kit comprises: an M reagent, an R reagent, a C-P calibrator, a pH adjuster, a reaction enhancer, and a chemiluminescent substrate. The M reagent contains a magnetic particle coated with a C peptide-biotinylated antibody at aconcentration of 2[mu]g/mL, and a Tris buffer solution at a concentration of 0.2mol/L. The R reagent contains a C-P-AP labeled antibody at a concentration of 1[mu]g/mL, and a Tris buffer solution at aconcentration of 0.1mol/L. The C-P calibrator comprises two different concentrations of C-peptide samples and a 0.1mol/L concentration of Tris buffer solution. The assay kit for detecting C-peptide has advantages of strong specificity and good stability, thereby improving the sensitivity and specificity of the detection; has a good stability in the whole system; is simple in operation; and is suitable for use with a clinical full automatic chemiluminescence assay instrument.

Methods for synthesizing proinsulin polypeptides are described that include contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. Methods of synthesizing proinsulin polypeptide-oligomer conjugates are also provided as are proinsulin polypeptide-oligomer conjugates. Methods of synthesizing C-peptide polypeptide-oligomer conjugates and other pro-polypeptide-oligomer conjugates are also provided.

The invention discloses an anti-C-peptide monoclonal antibody and a use thereof in detection of C-peptide content. According to the invention, C-peptide-GST and C-peptide-Trx are used as immunogens, two hybridoma cell strains are obtained by cell fusion technique-based screening, the microbial preservation numbers of the two hybridoma cell strains are respectively CGMCC NO. 6804 and CGMCC NO.6805, two monoclonal antibodies secreted by the two hybridoma cell strains can mutually matched, the content of C-peptide in serum is detected by double-antibody sandwich ELISA method, and the detection result has high accuracy and sensitivity.

The invention provides a method for constructing a related intestinal canal-pancreatic islet regulation axis function evaluation model. The method includes: allowing a subject to take different oral hypoglycemic drugs or blank control in different stages, then performing intravenous-oral dual hyperglycemic clamp tests on the subject in each stage, drawing an area under the curve for a serum insulin value, a C-peptide value, a plasma glucagon value and an active glucagon-like polypeptide-1 (GLP-1) value acquired through the dual hyperglycemic clamp tests in each stage, and applying Metlab to perform 3D (three-dimensional surface fitting on the areas under the curve in one-to-one correspondence to obtain the related intestine-pancreas axis function evaluation model. By the method, two-phase insulin secretion patterns in intravenous-oral glucose stimulation states can be evaluated and compared accurately, besides, intestinal canal hormone effect and insulin-glucagon secretion can be related quantitatively, and accordingly an accurate intestine-pancreas axis effect model evaluation system is obtained.